GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon Pharma Indonesia PT (ISX:SCPI) » Definitions » Debt-to-EBITDA

Organon Pharma Indonesia PT (ISX:SCPI) Debt-to-EBITDA : 0.00 (As of . 20)


View and export this data going back to 1990. Start your Free Trial

What is Organon Pharma Indonesia PT Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Organon Pharma Indonesia PT's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was Rp0.00 Mil. Organon Pharma Indonesia PT's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was Rp0.00 Mil. Organon Pharma Indonesia PT's annualized EBITDA for the quarter that ended in . 20 was Rp0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Organon Pharma Indonesia PT's Debt-to-EBITDA or its related term are showing as below:

ISX:SCPI's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.61
* Ranked among companies with meaningful Debt-to-EBITDA only.

Organon Pharma Indonesia PT Debt-to-EBITDA Historical Data

The historical data trend for Organon Pharma Indonesia PT's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Pharma Indonesia PT Debt-to-EBITDA Chart

Organon Pharma Indonesia PT Annual Data
Trend
Debt-to-EBITDA

Organon Pharma Indonesia PT Quarterly Data
Debt-to-EBITDA

Competitive Comparison of Organon Pharma Indonesia PT's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Organon Pharma Indonesia PT's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organon Pharma Indonesia PT's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organon Pharma Indonesia PT's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Organon Pharma Indonesia PT's Debt-to-EBITDA falls into.



Organon Pharma Indonesia PT Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Organon Pharma Indonesia PT's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Organon Pharma Indonesia PT's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (. 20) EBITDA data.


Organon Pharma Indonesia PT  (ISX:SCPI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Organon Pharma Indonesia PT Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Organon Pharma Indonesia PT's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Organon Pharma Indonesia PT (ISX:SCPI) Business Description

Traded in Other Exchanges
N/A
Address
Jalan Jend Sudirman Kav 21, Sinarmas MSIG Tower, Floor 37 Unit 102 & 106, South Jakarta, IDN, 12920
Organon Pharma Indonesia PT engages in the development, manufacture, and distribution of pharmaceutical products. It operates through manufacturing and commercial segments. Manufacturing, which generates the majority of the revenue, is engaged in pharmaceutical manufacturing.

Organon Pharma Indonesia PT (ISX:SCPI) Headlines

No Headlines